These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 23628617)

  • 41. Addition of once daily prandial lixisenatide to basal insulin therapy in patients with type-2 diabetes results in a reduction of HbA1c as an effect of postprandial glucose lowering.
    Fleischmann H; Göke R; Bramlage P
    Diabetes Metab Syndr; 2017 Nov; 11 Suppl 1():S91-S97. PubMed ID: 27986406
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus.
    Giorgino F; Caruso I; Napoli R
    Diabetes Res Clin Pract; 2020 Dec; 170():108478. PubMed ID: 33002548
    [TBL] [Abstract][Full Text] [Related]  

  • 43. iGlarLixi, a titratable once-daily fixed-ratio combination of basal insulin and lixisenatide for intensifying type 2 diabetes management for patients inadequately controlled on basal insulin with or without oral agents.
    Skolnik N; Dupree RS; Johnson EL
    Curr Med Res Opin; 2017 Dec; 33(12):2187-2194. PubMed ID: 28741967
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of unmet medical need among Japanese patients with type 2 diabetes mellitus and efficacy of Lixisenatide treatment among Asian type 2 diabetes mellitus patients.
    Terauchi Y; Naito Y; Ikeda Y
    Diabetes Metab Syndr; 2016; 10(1):23-8. PubMed ID: 26341928
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of Type 2 Diabetes Duration on the Efficacy and Safety of Add-on Lixisenatide in Asian Individuals Receiving Basal Insulin: A Pooled Analysis.
    Yao J; Zhang M; Zhang X; Zhang J
    Diabetes Ther; 2023 Apr; 14(4):653-669. PubMed ID: 36809495
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes.
    Horowitz M; Rayner CK; Jones KL
    Adv Ther; 2013 Feb; 30(2):81-101. PubMed ID: 23423907
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lixisenatide as add-on treatment among patients with different β-cell function levels as assessed by HOMA-β index.
    Bonadonna RC; Blonde L; Antsiferov M; Berria R; Gourdy P; Hatunic M; Mohan V; Horowitz M
    Diabetes Metab Res Rev; 2017 Sep; 33(6):. PubMed ID: 28303626
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis.
    Charbonnel B; Bertolini M; Tinahones FJ; Domingo MP; Davies M
    J Diabetes Complications; 2014; 28(6):880-6. PubMed ID: 25130920
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.
    Christensen M; Miossec P; Larsen BD; Werner U; Knop FK
    Expert Opin Drug Discov; 2014 Oct; 9(10):1223-51. PubMed ID: 25119443
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Predictors of outcomes in patients with type 2 diabetes in the lixisenatide GetGoal clinical trials.
    Blonde L; Chava P; Dex T; Lin J; Nikonova EV; Goldenberg RM
    Diabetes Obes Metab; 2017 Feb; 19(2):275-283. PubMed ID: 27767249
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of Type 2 diabetes mellitus.
    Aronson R
    Expert Rev Clin Pharmacol; 2013 Nov; 6(6):603-12. PubMed ID: 24147558
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
    Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
    Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Linagliptin improves glycemic control after 1 year as add-on therapy to basal insulin in Asian patients with type 2 diabetes mellitus.
    Sheu WH; Park SW; Gong Y; Pinnetti S; Bhattacharya S; Patel S; Seck T; Woerle HJ
    Curr Med Res Opin; 2015 Mar; 31(3):503-12. PubMed ID: 25629790
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term safety of once-daily lixisenatide in Japanese patients with type 2 diabetes mellitus: GetGoal-Mono-Japan.
    Seino Y; Yabe D; Takami A; Niemoeller E; Takagi H
    J Diabetes Complications; 2015; 29(8):1304-9. PubMed ID: 26342556
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials.
    Yabe D; Ambos A; Cariou B; Duvnjak L; Evans M; González-Gálvez G; Lin J; Nikonova EV; de Pablos-Velasco P; Yale JF; Ahrén B
    J Diabetes Complications; 2016; 30(7):1385-92. PubMed ID: 27267268
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin.
    Chamarthi B; Cincotta AH
    Postgrad Med; 2017 May; 129(4):446-455. PubMed ID: 28374645
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Achieving postprandial glucose control with lixisenatide improves glycemic control in patients with type 2 diabetes on basal insulin: a post-hoc analysis of pooled data.
    Davidson JA; Stager W; Paranjape S; Berria R; Leiter LA
    Clin Diabetes Endocrinol; 2020; 6():2. PubMed ID: 31956422
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lixisenatide versus insulin glulisine on top of insulin glargine in patients with type 2 diabetes mellitus: a cost-per-responder analysis in China.
    Men P; Li C; Zhai S; Qu S
    Curr Med Res Opin; 2020 Feb; 36(2):213-217. PubMed ID: 31469303
    [No Abstract]   [Full Text] [Related]  

  • 59. Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world.
    Dailey G; Bajaj HS; Dex T; Groleau M; Stager W; Vinik A
    BMJ Open Diabetes Res Care; 2019; 7(1):e000581. PubMed ID: 31114694
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lixisenatide: A New Daily GLP-1 Agonist for Type 2 Diabetes Management.
    McCarty D; Coleman M; Boland CL
    Ann Pharmacother; 2017 May; 51(5):401-409. PubMed ID: 28133970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.